Patents Assigned to Novalead Pharma Inc
  • Therapeutic agent for phosphodiesterase inhibition and its related disorders
    Patent number: 11786492
    Abstract: The pharmaceutical composition for treatment of phosphodiesterase related disorders comprises of administering to the subject a therapeutically effective amount of a compound of Formula-I, or compounds selected from the group consisting of Niclosamide, Oxyclozanide, Rafoxanide, Closantel, Dibromsalan, Metabromsalan, Tribromsalan and Nitazoxanide, and prodrugs, metabolites, or pharmaceutically acceptable salts, solvates and polymorphs thereof in a pharmaceutically acceptable carrier, vehicle, or diluents.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: October 17, 2023
    Assignees: Novalead Pharma Inc
    Inventors: Supreet K. Deshpande, Sudhir A. Kulkarni, Atul S. Aslekar
  • Therapeutic Agent For Phosphodiesterase Inhibition And Its Related Disorders
    Publication number: 20220000813
    Abstract: The pharmaceutical composition for treatment of phosphodiesterase related disorders comprises of administering to the subject a therapeutically effective amount of a compound of Formula-I, or compounds selected from the group consisting of Niclosamide, Oxyclozanide, Rafoxanide, Closantel, Dibromsalan, Metabromsalan, Tribromsalan and Nitazoxanide, and prodrugs, metabolites, or pharmaceutically acceptable salts, solvates and polymorphs thereof in a pharmaceutically acceptable carrier, vehicle, or diluents.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 6, 2022
    Applicants: Novalead Pharma Inc
    Inventors: Supreet K. DESHPANDE, Sudhir A. KULKARNI, Atul S. ASLEKAR
  • Therapeutic agent for phosphodiesterase inhibition and its related disorders
    Patent number: 11147779
    Abstract: The pharmaceutical composition for treatment of phosphodiesterase related disorders comprises of administering to the subject a therapeutically effective amount of a compound of Formula-I, or compounds selected from the group consisting of Niclosamide, Oxyclozanide, Rafoxanide, Closantel, Dibromsalan, Metabromsalan. Tribromsalan and Nitazoxanide, and prodrugs, metabolites, or pharmaceutically acceptable salts, solvates and polymorphs thereof in a pharmaceutically acceptable carrier, vehicle, or diluents.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: October 19, 2021
    Assignees: Novalead Pharma Inc
    Inventors: Supreet K. Deshpande, Sudhir A. Kulkarni, Atul S. Aslekar